AOL Money & Finance

Options update 1-3-08: Sciele Pharma volatility elevated after FDA approval

More

Sciele Pharma (NASDAQ: SCRX) announced the FDA approved its new formulation of Sular (high blood pressure treatment).

SCRX closed at $19.84 Wednesday.

Friedman BIlings says: "Successful execution of the Sular switch will remain a concern for investors and depress the near-term share valuation."

SCRX January option implied volatility of 82 is above its 26-week average of 48 according to Track Data, suggesting larger risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Symbol Lookup
IndexesChangePrice
DJIA-154.4810,309.92
NASDAQ-37.612,138.44
S&P 500-19.141,091.49

Last updated: November 27, 2009: 07:04 PM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

TheFlyOnTheWall.com Headlines

BioHealth Investor Headlines

WalletPop Headlines

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

WalletPop Headlines